AVEO Pharmaceuticals (AVEO)
AVEO Pharmaceuticals Earnings Yield: -18.33%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AVEO Earnings Yield Rankings
| Overall | 11th percentile | 3798 of 4312 |
| Sector | 26th percentile | 363 of 492 in Healthcare |
| Industry | 38th percentile | 96 of 155 in Biotechnology |
AVEO Earnings Yield Range, Past 5 Years
| Minimum | -264.2% | Mar 2010 |
| Maximum | 17.15% | Sep 2011 |
| Average | -60.76% |
About Earnings Yield
Earnings yield is earnings per share from the previous four quarters divided by the share price. It is the reciprocal of the P/E ratio. The earnings yield is quoted as a percentage, which illustrates the percentage of each dollar invested that was earned by the company during the past twelve months.
The earnings yield can be used to compare the earnings of a stock, sector or the whole market against bond yields. Generally, the earnings yields of equities are higher than the yield of risk-free treasury bonds. Financial theorists argue that this difference exists because stock earnings are riskier than bond coupon payments.
If a company has an earnings yield of 64%, investors are purchasing $0.64 of earnings per dollar invested.
Learn More
You may also be interested in these AVEO related companies
AVEO News
AVEO Oncology (AVEO) Commences AV-203 Phase 1 in Advanced Solid Tumors
May 23, 9:19AM Street Insider
May 23, 9:19AM Street Insider
$AVEO is -5.2% down since open on unusual high volume and -6.4% down since close.
about 10 days ago by TradeBot
about 10 days ago by TradeBot
RT @justfurkids ASCO12 "Most significant cancer drug data came from $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgp
about 11 days ago by russe9
about 11 days ago by russe9
ASCO12 "Most significant cancer drug data came from phase III studies by $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgj
about 11 days ago by justfurkids
about 11 days ago by justfurkids
AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
May 16, 6:05PM Business Wire
May 16, 6:05PM Business Wire
$AVEO http://stks.co/3lp8 from watch list and up to first resistance line on volume of 85% full day average
about 17 days ago by StockTiger
about 17 days ago by StockTiger
New 126,000 Square Foot Lease at 650 East Kendall Street Signed By BioMed Realty
May 10, 9:17AM PR Newswire
May 10, 9:17AM PR Newswire
Market Wrap Video + Additions to Watch List http://stks.co/3lOk including: $AH $COG $SJT $RRC $SNTS $AVEO $RYL
about 17 days ago by StockTiger
about 17 days ago by StockTiger
Listen to $AVEO AVEO Pharmaceuticals, Inc. at Deutsche Bank AG Health Care Confe - live at 03:30 PM, ondemand after - http://stks.co/3j9m
about 19 days ago by earningscast
about 19 days ago by earningscast
Canaccord Genuity Maintains a 'Buy' on AVEO Pharmaceuticals (AVEO); Q1 In-line; Waiting on P3 TIVO-1 Data at ASCO
May 04, 11:39AM Street Insider
May 04, 11:39AM Street Insider
News related to $AVEO: 'Aveo takes 1Q loss as drug development continues' http://stks.co/3exU
about 24 days ago by TradeBot
about 24 days ago by TradeBot
Listen to $AVEO Q1 2012 earnings call - live at 10:00 AM, ondemand after - http://stks.co/3eFW
about 24 days ago by earningscast
about 24 days ago by earningscast
AVEO Reports First Quarter 2012 Financial Results and Recent Developments
May 03, 6:30AM Business Wire
May 03, 6:30AM Business Wire
AVEO Pharma (AVEO) Says Ficlatuzumab and Gefitinib Phase 2 Did Not Show Statistical Significance
May 02, 6:37AM Street Insider
May 02, 6:37AM Street Insider
AVEO Pharmaceuticals, Inc. to Present at Upcoming Investment Conferences
Apr 30, 6:30AM Business Wire
Apr 30, 6:30AM Business Wire
RT @stt2318 $AVEO looks bouncy down here <~ I agree after 11.10 is taken out
about 31 days ago by ACE52WeekHigh
about 31 days ago by ACE52WeekHigh
AVEO Pharmaceuticals, Inc. Announces Timing for First Quarter Financial Results, Webcast and Conference Call
Apr 26, 6:30AM Business Wire
Apr 26, 6:30AM Business Wire
AVEO Pharma (AVEO) Reports Publication of Positive Bivozanib Phase 2 Data; Will Submit NDA in Q312
Apr 12, 6:35AM Street Insider
Apr 12, 6:35AM Street Insider
AVEO Announces Publication of Positive Tivozanib Phase 2 Clinical Trial Results in Journal of Clinical Oncology
Apr 12, 6:30AM Business Wire
Apr 12, 6:30AM Business Wire
7 cancer stocks to have on your radar screen before ASCO conf meets in June: $CLDX $ARQL $JNJ $ARIA $AVEO $ARRY $ONTY http://stks.co/3FYc
about 51 days ago by abubnic
about 51 days ago by abubnic
Data on AVEO Pharmaceuticals’ Tivozanib and AV-203 to Be Presented at AACR Annual Meeting 2012
Mar 27, 6:30AM Business Wire
Mar 27, 6:30AM Business Wire
URGENT: $AVEO filed to delay releasing annual earnings results (SEC Filing Form NT 10K) http://stks.co/2uYb
about 72 days ago by MarketBrief
about 72 days ago by MarketBrief
$AVEO New 52 Week Low - Crossed daily lows support. Next support 11.24 from 10/1/2010.
about 76 days ago by TradeIdeasQuant
about 76 days ago by TradeIdeasQuant
AVEO Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 27, 6:30AM Business Wire
Feb 27, 6:30AM Business Wire
Canaccord Genuity Maintains a 'Buy' on AVEO Pharmaceuticals (AVEO); Awaiting TIVO-1 ASCO Presentation
Feb 15, 9:46AM Street Insider
Feb 15, 9:46AM Street Insider
AVEO Reports 2011 Financial Results and Highlights Fourth Quarter Progress
Feb 14, 6:30AM Business Wire
Feb 14, 6:30AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AVEO | 12.60 | +0.41 | +3.36% | 544.95M |
| AVD | 25.75 | -0.01 | -0.04% | 710.96M |
| AVCA | 6.199 | +0.26 | +4.36% | 36.08M |
| AVB | 139.84 | -1.30 | -0.92% | 13.31B |
| AVAV | 21.53 | -0.11 | -0.51% | 475.81M |
| AVA | 25.45 | -0.04 | -0.16% | 1.490B |
| BAMM | 3.24 | +0.02 | +0.62% | 51.22M |
| BAM | 31.76 | +0.16 | +0.51% | 19.77B |
| BALT | 3.80 | -0.07 | -1.81% | 64.60M |
| BAK | 11.30 | +0.15 | +1.35% | 2.552B |
